Study guide

4.3 Hepatic Blood Flow, Metabolism, and Clearance

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

4.3 Hepatic Blood Flow, Metabolism, and Clearance

Key Takeaways Explain This Topic AI

The liver receives a dual blood supply of ~1.5 L/min (25% of cardiac output), with the portal vein providing 75% of flow and 50% of oxygen, and the hepatic artery providing 25% of flow and 50% of oxygen.

The Hepatic Arterial Buffer Response (HABR) is a unidirectional mechanism mediated by adenosine washout in the periportal space of Mall: reduced portal venous flow causes local adenosine accumulation and compensatory hepatic arterial vasodilation.

Drugs with a high hepatic extraction ratio ( E H > 0.7 E_H > 0.7 E H ​ > 0.7 , e.g., propofol, lidocaine, morphine) exhibit flow-limited clearance sensitive to cardiac output and liver perfusion, whereas low extraction ratio drugs ( E H < 0.3 E_H < 0.3 E H ​ < 0.3 , e.g., diazepam, rocuronium) exhibit capacity-limited clearance governed by enzyme activity and protein binding.

Phase I biotransformation functionalizes lipophilic molecules via Cytochrome P450 oxidation, reduction, or hydrolysis, while Phase II conjugation couples hydrophilic groups (glucuronidation, sulfation) to facilitate biliary or urinary elimination.

The liver synthesizes almost all circulating plasma proteins and clotting factors, with the critical exception of Factor VIII and von Willebrand factor, which are produced primarily by vascular endothelial cells.

Last updated: October 2026

4.3 Hepatic Blood Flow, Metabolism, and Clearance

The liver is the primary metabolic clearinghouse for anaesthetic drugs, the source of essential circulating proteins, and the central regulator of intermediary metabolism. Thorough comprehension of hepatic vascular anatomy, autoregulatory buffering, biotransformation pathways, and pharmacokinetic models of clearance is required for safe perioperative patient care.

  • 1. Dual Hepatic Microcirculation and Oxygenation
  • Dual Vascular Architecture

Total hepatic blood flow ( Q H Q_H Q H ​ ) averages 1.5 L/min in an adult (~100 mL/100g/min of liver tissue), representing 25% of resting cardiac output :

Portal Vein (~75% of flow, ~1100 mL/min): Formed by the confluence of the splenic vein and superior mesenteric vein, draining the venous outflow of the gastrointestinal tract, spleen, and pancreas. It is a low-pressure system ( 7 to 10 mmHg ). Although venous, it supplies 50% of the liver's total oxygen supply due to its sheer volume. Oxygen saturation is intermediate ( S p v O 2 ≈ 65 – 75 % S_{pv}\text{O}_2 \approx 65\text{--}75\% S p v ​ O 2 ​ ≈ 65 – 75% in the fasting state, dropping to ~45–50% during active digestion). Portal flow is largely passive and lacks intrinsic autoregulation; it depends on upstream splanchnic arteriolar tone and post-sinusoidal resistance.

Hepatic Artery (~25% of flow, ~400 mL/min): Originates from the celiac axis via the common hepatic artery. It is a high-pressure system (mean pressure matches systemic MAP ~90 mmHg ) delivering fully oxygenated blood ( S a O 2 ≈ 98 % S_a\text{O}_2 \approx 98\% S a ​ O 2 ​ ≈ 98% ), providing the remaining 50% of hepatic oxygen delivery . The hepatic artery possesses muscular walls with active autoregulatory and autonomic control. Dual Hepatic Inflow

  • Portal Vein (75%) Hepatic Artery (25%)
  • ~1100 mL/min, 7-10 mmHg ~400 mL/min, MAP ~90 mmHg
  • 50% of O2 Delivery 50% of O2 Delivery
  • \ /
  • \ /
  • v v
  • Hepatic Sinusoids (2-4 mmHg)
  • Low pressure, fenestrated
  • Space of Disse (exchange)
  • |
  • v
  • Central Veins
  • |
  • v
  • Hepatic Veins
  • |
  • v
  • Inferior Vena Cava (IVC)
  • Sinusoidal Microcirculation

Within the microscopic liver lobules and acini:

Branches of the portal venules and hepatic arterioles merge at the periphery of the hepatic lobule to discharge mixed blood into the hepatic sinusoids .

Sinusoids are low-pressure channels ( 2 to 4 mmHg ) that direct blood centripetally past plates of hepatocytes toward the central lobular vein .

Discontinuous endothelial lining: Sinusoidal endothelial cells possess large fenestrations (100–200 nm) and lack a basement membrane. Plasma filters freely into the space of Disse (the perisinusoidal space separating endothelial cells from hepatocyte microvilli), allowing direct, unhindered contact between plasma proteins, drugs, and hepatocytes.

Reticuloendothelial system: Kupffer cells (tissue-resident macrophages) anchor within the sinusoidal lumen, phagocytosing bacteria, endotoxins, and cellular debris cleared from the splanchnic circulation.

2. The Hepatic Arterial Buffer Response (HABR)

Because portal venous blood flow is dictated by the metabolic and digestive activity of upstream gastrointestinal organs, the liver cannot regulate portal inflow. To protect hepatic oxygenation from sudden reductions in portal flow, the liver possesses an intrinsic, compensatory vascular mechanism known as the Hepatic Arterial Buffer Response (HABR) .

The Adenosine Washout Mechanism

The HABR is explained by the adenosine washout hypothesis :

Adenosine is an endogenous vasodilator synthesized and secreted at a constant basal rate into the interstitial fluid surrounding the terminal microvessels in the periportal space of Mall .

When portal venous blood flow is normal or high, adenosine is continuously washed away into the sinusoids, keeping local periportal adenosine concentrations low.

If portal venous flow decreases (e.g., during splanchnic vasoconstriction, hemorrhage, systemic hypotension, or mesenteric traction), the washout rate of adenosine declines.

Local adenosine accumulates in the space of Mall and binds to vascular A 2 A_2 A 2 ​ purinergic receptors on adjacent hepatic arterioles.

Activation of A 2 A_2 A 2 ​ receptors stimulates adenylyl cyclase, elevating cAMP and opening potassium channels, which induces profound hepatic arterial vasodilation .

Hepatic arterial flow increases, restoring up to 60% of the lost total hepatic blood flow and defending hepatic oxygenation.

Strict Unidirectionality: A Crucial Clinical Vulnerability

The HABR is strictly unidirectional :

While reductions in portal flow trigger hepatic arterial dilatation, reductions in hepatic arterial flow do not produce any reciprocal increase in portal venous flow .

If hepatic arterial flow is compromised (e.g., accidental ligation during cholecystectomy or transplantation, or severe shock), the portal vein cannot compensate, and acute hepatocellular ischemia ensues.

3. Perioperative and Anaesthetic Influences on Hepatic Perfusion

Clinical Perturbation Effect on Hepatic Hemodynamics Mechanism and Clinical Implications

Volatile Agents (Isoflurane, Sevoflurane) Reduce total hepatic flow (15–30%); preserve hepatic arterial buffer Cause dose-dependent systemic hypotension and vasodilation; sevoflurane and isoflurane preserve HABR significantly better than halothane

Intravenous Agents (Propofol) Modest reduction in total flow in parallel with cardiac output Decreases arterial pressure and hepatic arterial flow; portal flow is relatively maintained; HABR remains functional

Positive Pressure Ventilation & PEEP Marked reduction in total hepatic perfusion High intrathoracic pressure elevates right atrial and hepatic venous pressure ( P h v P_{hv} P h v ​ ); narrows portal driving gradient ( P p v − P h v P_{pv} - P_{hv} P p v ​ − P h v ​ ); PEEP > 10 cmH 2 O >10\text{ cmH}_2\text{O} > 10 cmH 2 ​ O causes sinusoidal congestion

Laparoscopic Insufflation Reduces portal venous flow by 30–50% High intra-abdominal pressure ( > 12 – 15 mmHg >12\text{--}15\text{ mmHg} > 12 – 15 mmHg ) directly compresses mesenteric venules and inferior vena cava; partially compensated by HABR

Sympathetic Stress & Vasopressors Selective splanchnic and hepatic vasoconstriction Exogenous α 1 \alpha_1 α 1 ​ -agonists (phenylephrine, high-dose norepinephrine) constrict mesenteric arterioles, diminishing portal venous inflow

4. Pharmacokinetic Models of Hepatic Drug Clearance

Total hepatic clearance ( C L H CL_H C L H ​ ) represents the volume of blood completely cleared of drug by the liver per unit of time:

C L H = Q H × E H CL_H = Q_H \times E_H C L H ​ = Q H ​ × E H ​

Where Q H Q_H Q H ​ is total hepatic blood flow (~1.5 L/min) and E H E_H E H ​ is the hepatic extraction ratio :

E H = C in − C out C in = f u × C L int Q H + ( f u × C L int ) E_H = \frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}} = \frac{f_u \times CL_{\text{int}}}{Q_H + (f_u \times CL_{\text{int}})} E H ​ = C in ​ C in ​ − C out ​ ​ = Q H ​ + ( f u ​ × C L int ​ ) f u ​ × C L int ​ ​

Where C L int CL_{\text{int}} C L int ​ is the intrinsic clearance (the intrinsic enzymatic and biliary transport capacity of hepatocytes) and f u f_u f u ​ is the unbound (free) drug fraction in plasma.

  • High vs Low Extraction Ratio Drugs High Extraction Drugs (E > 0.7) Low Extraction Drugs (E < 0.3)
  • ============================== =============================
  • Rate-limiting step: BLOOD FLOW Rate-limiting step: ENZYME CAPACITY
  • Flow-limited (perfusion-dependent) - Capacity-limited (enzyme-dependent)
  • CL_H ≈ Q_H - CL_H ≈ f_u × CL_int
  • Sensitive to: Cardiac output, PEEP - Sensitive to: Cirrhosis, CYP induction
  • Examples: Propofol, Lidocaine, Morphine - Examples: Diazepam, Rocuronium, Warfarin
  • High Extraction Ratio Drugs ( E H > 0.7 E_H > 0.7 E H ​ > 0.7 )

Pharmacological Behavior: Hepatocytes metabolize the drug so rapidly and efficiently that intrinsic clearance far exceeds liver blood flow ( f u × C L int ≫ Q H f_u \times CL_{\text{int}} \gg Q_H f u ​ × C L int ​ ≫ Q H ​ ). Thus, the mathematical denominator simplifies, yielding:

C L H ≈ Q H CL_H \approx Q_H C L H ​ ≈ Q H ​

Rate-Limiting Factor: Delivery of drug to the liver ( perfusion-dependent or flow-limited clearance ).

Key Examples: Propofol , lidocaine , morphine , fentanyl , sufentanil , ketamine , propranolol , nitroglycerin .

Clinical Implications: Changes in hepatic blood flow (e.g., heart failure, shock, hemorrhage, high PEEP, beta-blockade) directly dictate clearance. A 50% drop in cardiac output halves propofol clearance, leading to drug accumulation. In contrast, displacement from plasma protein binding or mild enzyme induction has minimal impact on systemic clearance. These drugs undergo extensive first-pass metabolism, resulting in poor oral bioavailability.

Low Extraction Ratio Drugs ( E H < 0.3 E_H < 0.3 E H ​ < 0.3 )

Pharmacological Behavior: Hepatocyte metabolic capacity is the rate-limiting step; organ blood flow far exceeds the ability of enzymes to clear the drug ( Q H ≫ f u × C L int Q_H \gg f_u \times CL_{\text{int}} Q H ​ ≫ f u ​ × C L int ​ ). Thus:

C L H ≈ f u × C L int CL_H \approx f_u \times CL_{\text{int}} C L H ​ ≈ f u ​ × C L int ​

Rate-Limiting Factor: Intrinsic microsomal enzyme activity and free unbound drug fraction ( capacity-limited or enzyme-dependent clearance ).

Key Examples: Diazepam , lorazepam , alfentanil , rocuronium , vecuronium , methohexital , phenytoin , warfarin , theophylline .

Clinical Implications: Fluctuations in liver blood flow have virtually no effect on clearance. Clearance is profoundly impaired by liver cirrhosis, hypothermia, acute hepatitis, and CYP enzyme inhibition. Alterations in plasma protein binding (e.g., hypoalbuminemia) alter the free fraction ( f u f_u f u ​ ), dramatically shifting active unbound drug concentrations.

Intermediate Extraction Ratio Drugs ( E H = 0.3 to 0.7 E_H = 0.3\text{ to } 0.7 E H ​ = 0.3 to 0.7 )

Examples: Midazolam , methadone , codeine .

Behavior: Clearance is sensitive to both hepatic blood flow and intrinsic enzymatic activity.

5. Pathways of Biotransformation: Phase I and Phase II Reactions

Biotransformation converts lipophilic, non-polar drugs into hydrophilic, polar metabolites suitable for excretion in bile or urine.

Phase I Reactions: Functionalization

Chemical reactions: Oxidation , reduction , and hydrolysis . Introduces or unmasks a polar functional group (e.g., − O H -OH − O H , − N H 2 -NH_2 − N H 2 ​ , − S H -SH − S H , − C O O H -COOH − COO H ). Metabolites may be inactive, less active, or occasionally more potent or toxic than the parent compound.

Cytochrome P450 (CYP) hemoproteins: Superfamily of membrane-bound enzymes located in the smooth endoplasmic reticulum (microsomes) of hepatocytes. They utilize molecular oxygen and electrons donated from NADPH via NADPH-CYP oxidoreductase: Drug + O 2 + NADPH + H + → CYP Drug-OH + H 2 O + NADP + \text{Drug} + O_2 + \text{NADPH} + H^+ \xrightarrow{\text{CYP}} \text{Drug-OH} + H_2O + \text{NADP}^+ Drug + O 2 ​ + NADPH + H + CYP ​ Drug-OH + H 2 ​ O + NADP +

Major CYP Isoforms in Anaesthesia:

CYP3A4/5 (~50% of all clinical drugs): Metabolizes fentanyl, sufentanil, alfentanil, midazolam, lidocaine, bupivacaine, dexmedetomidine, and calcium channel blockers. Inhibitors: azole antifungals, erythromycin, ciprofloxacin, cimetidine, grapefruit juice. Inducers: rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort.

CYP2D6: Responsible for the metabolic activation of opioid prodrugs: bioactivation of codeine to morphine and tramadol to O-desmethyltramadol (M1) . Also clears ondansetron and metoprolol. Exhibits profound genetic polymorphism: poor metabolizers experience no analgesia from codeine or tramadol, whereas ultrarapid metabolizers (gene duplication) risk fatal respiratory depression from standard codeine doses.

CYP2E1: Metabolizes volatile inhalational agents (halothane, isoflurane, sevoflurane) and paracetamol (acetaminophen). Induced by chronic ethanol intake. Halothane oxidation generates reactive trifluoroacetyl chloride, which acetylates hepatocyte surface proteins, eliciting immune-mediated halothane hepatitis .

Non-Microsomal and Extrahepatic Phase I Mechanisms:

Plasma pseudocholinesterase (butyrylcholinesterase): Synthesized in the liver; hydrolyzes succinylcholine and mivacurium .

Non-specific tissue and blood esterases: Clear remifentanil and esmolol , resulting in ultra-short context-sensitive half-times independent of hepatic or renal function.

Hofmann elimination: Spontaneous, non-enzymatic chemical breakdown of atracurium and cisatracurium at normal physiological pH and temperature.

Phase II Reactions: Conjugation

Mechanism: Covalent attachment of an endogenous, highly polar, hydrophilic substrate to a functional group on the parent drug or its Phase I metabolite. Phase II reactions almost universally yield inactive, non-toxic, water-soluble products excreted by the kidneys or biliary tract.

Glucuronidation (UDP-glucuronosyltransferases, UGT): Most prevalent conjugation pathway. Transfers glucuronic acid from UDP-glucuronic acid to substrates. Clears propofol , morphine , and paracetamol . Morphine is converted mainly into morphine-3-glucuronide (M3G, roughly 55–75%) , which has no analgesic activity and may be neuroexcitatory, and morphine-6-glucuronide (M6G, about 10%) , a μ \mu μ -agonist more potent than morphine that accumulates in renal failure.

Sulfation (sulfotransferases, SULT): Cytosolic pathway conjugating sulfate.

Acetylation (N-acetyltransferases, NAT1/NAT2): Clears hydralazine, procainamide, and isoniazid. Polymorphism produces "slow acetylators" prone to drug-induced lupus.

Glutathione Conjugation (Glutathione S-transferase, GST): Essential detoxifying pathway. Neutralizes the toxic, electrophilic Phase I metabolite of paracetamol, NAPQI (N-acetyl-p-benzoquinone imine) . In paracetamol overdose, hepatic glutathione stores are depleted (>70%); excess NAPQI binds to hepatocyte mitochondrial proteins, causing centrilobular necrosis. Treatment with N-acetylcysteine (NAC) restores intracellular glutathione synthesis.

  • 6. Synthetic and Coagulation Functions of the Liver
  • Plasma Protein Synthesis

Albumin: Synthesized exclusively by hepatocytes at 12 to 15 g/day (half-life: 20 days ). Maintains 75–80% of plasma oncotic pressure and binds acidic drugs (thiopental, propofol, phenytoin, warfarin). Due to its long half-life, albumin is a marker of chronic, rather than acute, hepatic dysfunction.

Alpha-1 Acid Glycoprotein (AAG): Acute-phase reactant that binds basic drugs (local anaesthetics, opioids). Serum concentrations rise acutely during inflammation, surgical trauma, and sepsis, lowering the free unbound fraction of local anaesthetics and reducing the risk of systemic toxicity (LAST).

Coagulation Factor Synthesis: The Factor VIII Exception

The liver synthesizes almost all circulating procoagulant and anticoagulant proteins:

Procoagulants: Fibrinogen (I), Prothrombin (II), Factor V, Factor VII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII.

Vitamin K-dependent factors: Factors II, VII, IX, and X , along with anticoagulant proteins C and S . They require post-translational γ \gamma γ -carboxylation of glutamic acid residues catalyzed by vitamin K-dependent carboxylase.

Natural Anticoagulants: Antithrombin III, Protein C, Protein S.

The Critical EDAIC Exception: Factor VIII and von Willebrand factor (vWF) are NOT synthesized by hepatocytes! They are synthesized and released by vascular endothelial cells throughout the body and sinusoidal endothelial cells. In severe acute liver failure or advanced cirrhosis, Factor VIII levels are characteristically normal or elevated (due to acute-phase endothelial release). If Factor VIII is depleted, disseminated intravascular coagulation (DIC) or a primary hematologic disorder must be suspected.

Diagnostic Sensitivity: Factor VII has the shortest biological half-life of any clotting factor ( 4 to 6 hours ). Consequently, prothrombin time (PT) and International Normalized Ratio (INR) are the most sensitive laboratory markers of acute hepatocellular failure.